Achillion Pharmaceuticals Inc., of New Haven, Conn., appointed Elizabeth A. Olek vice president and chief medical officer.

Actelion Ltd., of Allschwil, Switzerland, named Otto Schwarz head of business operations.

ARIAD Pharmaceuticals Inc., of Cambridge, Mass., appointed Matthew E. Ros vice president of oncology marketing, Virginia R. Dean vice president of human resources and Frank G. Haluska senior medical director.

ART Advanced Research Technologies Inc., of Montreal, named Rik van Heijningen director of its European commercial operations in preclinical imaging.

Aurogen Inc., of Fort Collins, Colo., named Robert F. Caspari president and chief executive officer.

Biodel Inc., of Danbury, Conn., appointed Brian J.G. Pereira to its board of directors.

Celator Pharmaceuticals, of Princeton, N.J., named Frederick R. Appelbaum and Ross C. Donehower to its scientific advisory board.

Corium International Inc., of Menlo Park, Calif., appointed Phyllis Gardner and Daniel G. Welch to its board of directors.

Cubist Pharmaceuticals Inc., of Lexington, Mass., named Bonnie Bassler, Eric Jacobsen and Richard White to its scientific advisory board.

Cytheris SA, of Paris, appointed Richard W. Keatinge chief business officer.

Evotec AG, of Hamburg, Germany, named Mario Polywka and Klaus Maleck to its management board.

Gene Express Inc., of Toledo, Ohio, named David Sidransky and Michael N. Liebman to its scientific advisory board.

Gene Logic Inc., of Gaithersburg, Md., appointed Bethany Mancilla senior vice president of business development.

HistoRx Inc., of New Haven, Conn., appointed Rana K. Gupta chief executive officer.

Immucor Inc., of Norcross, Ga., named Richard A. Flynt vice president and chief financial officer.

ImmunoGen Inc., of Cambridge, Mass., named John Tagliamonte vice president of business development.

Inhibitex Inc., of Atlanta, named Erik De Clercq chair of its scientific advisory board.

Kythera Biopharmaceuticals Inc., of Los Angeles, appointed John W. Smither chief financial officer.

Lev Pharmaceuticals Inc., of New York, named Henry M. Dachowitz to its board of directors.

LifeCycle Pharma AS, of Horsholm, Denmark, appointed Hans Christian Teisen senior vice president and chief financial officer.

Lixte Biotechnology Holdings Inc., of East Setauket, N.Y., appointed Stephen K. Carter to its board of directors.

Merrimack Pharmaceuticals Inc., of Cambridge, Mass., named Robert Gay to its board of directors.

Myriad Genetics Inc., of Salt Lake City, named Gerald P. Belle to its board of directors.

Neurobiological Technologies Inc., of Emeryville, Calif., appointed Warren Wasiewski chief medical officer.

Neuromed Pharmaceuticals, of Vancouver, British Columbia, named Jeffrey Arcara vice president of business development.

No Comments